Abstract
The Universal Definition of Myocardial Infarction globally endorses cardiac troponin (T and I; cTnT, cTnI) as the biomarker of choice for the diagnosis and assessment of acute coronary syndrome (ACS) and should be utilized routinely in patients with symptoms suggestive of acute myocardial infarction (AMI) [1]. Despite the widespread use of troponin in clinical practice there remain a number of pre-analytical, analytical and interpretive issues which can confound clinical interpretation and will likely be magnified with high-sensitivity troponin assays. The following case studies and discussion highlight some of these issues and nuances associated with troponin assays.
| Original language | English (US) |
|---|---|
| Title of host publication | Cardiac Biomarkers |
| Subtitle of host publication | Case Studies and Clinical Correlations |
| Publisher | Springer International Publishing |
| Pages | 3-15 |
| Number of pages | 13 |
| ISBN (Electronic) | 9783319429823 |
| ISBN (Print) | 9783319429809 |
| DOIs | |
| State | Published - Jan 1 2016 |
Keywords
- Acute coronary syndrome
- Antibody
- Biomarker
- Chest pain
- Hemolysis
- Heterophile
- High-sensitivity troponin
- Interferences
- Myocardial infarction
- Troponin